Cybin Inc. announced the presentation of four posters at the American College of Neuropsychopharmacology (ACNP) annual meeting taking place December 3-6, 2023, in Tampa, Florida. The data presented include topline data from its Phase 2 study of CYB003 in major depressive disorder (MDD) which showed rapid, robust, and clinically significant reduction of depression symptoms, preclinical data supporting the CYB004 (deuterated DMT) program, and preclinical data characterizing phenethylamine candidates from the CYB005 program. The study of CYB003 for MDD, it observed rapid and large improvements in symptoms of depression after single doses, with a clear incremental benefit of a second dose.

At the end of the double-blind phase (day 21) for the 12mg dose, CYB003 showed a rapid improvement with a clinically meaningful effect size (2.15) and statistically significant (p=0.0005) difference of 14 points on the Montgomery-Asberg Depression Rating Scale (MADRS) over placebo. Importantly, similar results were obtained in the 16mg group. Response and remission rates were also compelling, exceeding 75%.